Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing intratumoral alpha-emitting radiotherapeutics for solid tumors. The company’s proprietary Alpha DaRT technology utilizes alpha particles to deliver localized radiation therapy, targeting superficial lesions such as skin and head and neck cancers, as well as deep-seated tumors in the pancreas, brain, lung, prostate, rectum, and liver. Alpha Tau is currently conducting clinical trials for indications including cutaneous squamous cell carcinoma, recurrent glioblastoma multiforme, and pancreatic adenocarcinoma, with a focus on refractory or unresectable cases and combinations with systemic therapies like checkpoint inhibitors. The company has received marketing approval in Israel for the treatment of squamous cell carcinoma of the skin or oral cavity and pre-market approval in Japan for unresectable locally advanced or recurrent head and neck cancer. Alpha Tau also holds Breakthrough Device Designations from the U.S. Food and Drug Administration for these indications. Founded in 2015 by Uzi Sofer and inventors including Professor Itzhak Kelson and Professor Yona Keisari, the company collaborates with clinical sites in the United States, Japan, Canada, and France to advance its pipeline.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage alphatau.com
Sector Healthcare IR page alphatau.com/investors
Tags
oncology, radiotherapy, alpha particles, solid tumors, pancreatic cancer, glioblastoma, squamous cell carcinoma, intratumoral therapy, clinical-stage, Alpha DaRT
Press page alphatau.com/newsroom

Metrics

Valuation  
Market cap $ 1.377B
Market cap (USD) $ 1.377B
P/E -14.34
PEG —
P/BV 31.25
P/S —
P/OCF -107.44
P/FCF -85.43
Dividend yield —
Turnover / mcap —
Returns  
ROE -61.0%
ROI -51.1%
ROIC -38.0%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 8.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 123
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 105.652M 86.204M 107.388M 120.149M 42.215M 52.989M
Net profit -42.627M -31.75M -29.157M -33.762M -27.271M -8.882M
Free cash flow -32.756M -22.021M -24.359M -24.783M -14.739M -11.018M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 4.95 3.1 3.01 3.18 — —
Price performance 12m 0.6 0.03 -0.05 — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — 5.19M 7.67M 6.98M 7.37M
Cash and deposits (USD) 13.6M 1.84M 15.6M 23.2M 5.84M 12.7M 13.7M 12.2M
Right-of-use assets (USD) — — — — 5.81M 8.36M 7.61M 7.21M
Cash flow detail
Operating cash flow (USD) — -6.91M -7.25M -11.8M -23.9M -18M -19.8M -26.7M
Purchases of property, plant and equipment (USD) — -1.29M -3.77M -2.93M -904,000 -6.4M -2.24M -6.08M
Interest paid (cash effect) (USD) — -780,000 -541,000 -351,000 -237,000 -52,000 -321,000 -381,000
Income taxes paid (cash effect) (USD) — — -218,000 -103,000 -8,000 -16,000 -5,000 -4,000
Share-based compensation (USD) — 546,000 596,000 812,000 6.75M 7.93M 9.92M 10.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -8.2M -11M -14.7M -24.8M -24.4M -22M -32.8M
Income detail
Research and development expense (USD) — 6.64M 7.54M 11.4M 20.9M 26.4M 27M 32.1M
↳ 5y CAGR +32.4% +33.6%
Total comprehensive income (USD) — — -8.88M -27.3M -33.8M -29.2M -31.8M -42.6M
Comprehensive income to owners (USD) — — -8.88M -27.3M -33.8M -29.2M -31.8M -42.6M
Reported Mar 28, 2022 Mar 28, 2022 Mar 9, 2023 Mar 9, 2023 Mar 9, 2023 Mar 7, 2024 Mar 12, 2025 Mar 9, 2026

Operating KPIs — quarters

KPI Jun 23 Jun 24 Jun 25 Jun 26
Weighted average lease term (years) 10.8 10.41 9.5 8.54
Reported Aug 14, 2024 Aug 14, 2024 Aug 11, 2025 Aug 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- Follow-up scans in several of the patients show asymptomatic radiation necrosis, a known effect of focal radiation in previously irradiated brain tissue; whether these findings suggest necrosis or tumor recurrence is expected to become clearer with additional follow-up over the coming months -

- No definitive local recurrence observed in any treated patient -

- According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months -

- Conference call with principal investigator and the Company to be held tomorrow, Monday, November 16, 2026, at 8:30am ET -

JERUSALEM, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced updated interim results from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent glioblastoma (GBM).

- Call to Follow Presentation of New Data at Upcoming Society for Neuro-

Oncology SNO Conference –

JERUSALEM, Nov. 12, 2026 -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that it will host a conference call and webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET to discuss new interim results from REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy), its U.S. multicenter trial exploring the use of Alpha DaRT in patients with recurrent glioblastoma. The call will take place on the back of the presentation of the results at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), to be held Nov. 12-15, 2026, in Philadelphia.

The call will feature REGAIN principal investigator Dr. Joshua Palmer of The Ohio State University; Uzi Sofer, CEO of Alpha Tau; Robert Den, MD, Chief Medical Officer of Alpha Tau; and Raphi Levy, CFO of Alpha Tau.

Conference Call and Webcast Details

● Date: Monday, Nov. 16, 2026

● Time: 8:30 a.m.

JERUSALEM, Oct. 29, 2026 — Alpha Tau Medical Ltd. (Nasdaq and TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that its ordinary shares will be included in the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective Nov. 5, 2026.

  • Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings
  • TA-125 tracks the 125 largest and most prominent companies on the TASE

Alpha Tau’s ordinary shares have been dual listed on the Nasdaq and TASE markets since August 2026, and trade on the TASE under the Hebrew symbol דרטס, allowing investors the flexibility to trade in both US and Israeli currency during open trading hours of the respective markets.

The TA-125 index, considered by many Israeli investors to be the benchmark for assessing the TASE market, tracks 125 of the largest and most prominent companies traded on the TASE: the 35 companies in the exchange’s leading TA-35 index and the 90 companies in the TA-90 index. These indices are widely followed by Israeli investors, and the index funds that track them are expected to add Alpha Tau’s shares to their holdings. With its inclusion, Alpha Tau will be one of only three biomed companies in the TA-125.

Uzi Sofer, CEO of Alpha Tau, stated: “Joining the TA-90 and TA-125 indices within months of our dual listing will place us in good company among the leading companies traded on the Tel Aviv Stock Exchange. We believe inclusion will further raise our visibility with Israeli institutional investors, broaden our local shareholder base and increase trading in Tel Aviv. Greater liquidity would benefit all our shareholders globally, as we work to expand the reach of Alpha DaRT to cancer patients wherever they are.”

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to primarily affect the tumor and to spare healthy tissue surrounding it.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Other than its marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer and in Israel for products intended to treat Squamous Cell Carcinoma (SCC) of the Skin and Oral Cavity, the Alpha DaRT treatment has not been approved for commercialization or for use outside of an approved clinical trial. In addition, any statements or information that refer to the inclusion of Alpha Tau’s ordinary shares in the TA-90 and TA-125 indices, including the timing of such inclusion and its potential effects on Alpha Tau’s visibility with investors, its shareholder base and the trading and liquidity of its ordinary shares, as well as any statements or information that refer to the Alpha DaRT treatment, including its potential benefits and associated risks, safety, feasibility and efficacy, future applications and uses, and other expectations, beliefs and plans, including with respect to clinical trials, regulatory approvals and studies, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

[email protected]

Share:

You might also be interested in:

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

  • October 22, 2026

  • Press Releases

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Read More

  • October 19, 2026

  • Press Releases

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Read More

  • October 5, 2026

  • Press Releases

Alpha Tau to Participate in October Investor Conferences

Read More

  • September 2, 2026

  • Press Releases

Alpha Tau to Participate in September Investor Conferences

Read More

  • August 31, 2026

  • Press Releases

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

Read More

  • August 10, 2026

  • Press Releases

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Read More

Prompts

Alpha Tau Medical Ltd. (ticker DRTS), listed in United States.

ETFs Holding Alpha Tau Medical Ltd.

ETF Weight in ETF Shares Market value As of
EHLS 0.56% 25,202 $ 301.668K Nov 17, 2026
AVSD 0.00% 972 $ 11.635K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
DRTS canonical Common share — US nasdaq 14.91 USD 2026-09-30
DRTSW Warrant — US nasdaq 4.10 USD 2026-09-30